Recent advances in aptamer-based targeted drug delivery systems for cancer therapy

Gao, Fei; Yin, Jianhui; Chen, Yan; Guo, Chunmei; Hu, Honggang; Su, Jiacan

doi:10.3389/fbioe.2022.972933

Cited by 32 publications

(25 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the various types of biomaterials, targeted and responsive biomaterials are more suitable for OA applications due to their small size and localizable delivery. They are often designed and assembled into functional structures to ensure accurate drug delivery [19][20][21]. Currently, researchers developed various dual-functional biomaterials for OA treatment, such as cartilage-targeted combined enzyme/pH/ROS/NIR response [22][23][24][25], macrophage-targeted combined enzyme/ultrasound/pH response [26][27][28], and endothelial cell-targeted combined ultrasound response [29].…”

Section: Ivyspringmentioning

confidence: 99%

Targeted and responsive biomaterials in osteoarthritis

Li¹,

Zhang²,

Han³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative disease characterized by loss of articular cartilage and chronic inflammation, involving multiple cellular dysfunctions and tissue lesions. The non-vascular environment and dense cartilage matrix in the joints tend to block drug penetration, resulting in low drug bioavailability. There is a desire to develop safer and more effective OA therapies to meet the challenges of an aging world population in the future. Biomaterials have achieved satisfactory results in improving drug targeting, prolonging the duration of action, and achieving precision therapy. This article reviews the current basic understanding of the pathological mechanisms and clinical treatment dilemmas of OA, summarizes and discusses the advances for different kinds of targeted and responsive biomaterials in OA, seeking to provide new perspectives for the treatment of OA. Subsequently, limitations and challenges in clinical translation and biosafety are analyzed to guide the development of future therapeutic strategies for OA. As the need for precision medicine rises over time, emerging multifunctional biomaterials based on tissue targeting and controlled release will become an irreplaceable part of OA management.

show abstract

Section: Ivyspringmentioning

confidence: 99%

Targeted and responsive biomaterials in osteoarthritis

Li¹,

Zhang²,

Han³

et al. 2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…It has been studied that aptamers can be used for both (i) carrier systems for drug molecules by encapsulating nucleic acidintercalating drugs and (ii) engineered pro-drug system by covalently conjugating the aptamers with the drug molecules. 239 However, aptamer-drug complex systems face major limitations of insufficient drug release and aptamer binding to the target site. Hence, to overcome these limitations aptamermodified nanoparticles have been proposed in cancer therapeutics.…”

Section: ■ Liposomes In Solid Tumor Theranosticsmentioning

confidence: 99%

Engineered Liposomes in Interventional Theranostics of Solid Tumors

Kommineni

Chaudhari

Conde

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Engineered liposomal nanoparticles have unique characteristics as cargo carriers in cancer care and therapeutics. Liposomal theranostics have shown significant progress in preclinical and clinical cancer models in the past few years. Liposomal hybrid systems have not only been approved by the FDA but have also reached the market level. Nanosized liposomes are clinically proven systems for delivering multiple therapeutic as well as imaging agents to the target sites in (i) cancer theranostics of solid tumors, (ii) image-guided therapeutics, and (iii) combination therapeutic applications. The choice of diagnostics and therapeutics can intervene in the theranostics property of the engineered system. However, integrating imaging and therapeutics probes within lipid self-assembly “liposome” may compromise their overall theranostics performance. On the other hand, liposomal systems suffer from their fragile nature, site-selective tumor targeting, specific biodistribution and premature leakage of loaded cargo molecules before reaching the target site. Various engineering approaches, viz., grafting, conjugation, encapsulations, etc., have been investigated to overcome the aforementioned issues. It has been studied that surface-engineered liposomes demonstrate better tumor selectivity and improved therapeutic activity and retention in cells/or solid tumors. It should be noted that several other parameters like reproducibility, stability, smooth circulation, toxicity of vital organs, patient compliance, etc. must be addressed before using liposomal theranostics agents in solid tumors or clinical models. Herein, we have reviewed the importance and challenges of liposomal medicines in targeted cancer theranostics with their preclinical and clinical progress and a translational overview.

show abstract

“…In addition being therapeutic agents, aptamers are more widely employed as recognition elements for targeted delivery of therapeutic moieties, such as anticarcinogens, RNA oligonucleotides, toxins, nanoparticles, etc. [82][83][84] Aptamers can be conjugated to various drugs through cleavable or non-cleavable linkers to form aptamer-drug conjugates (ApDCs) for cancer therapy. These ApDCs show many advantages, including relatively small size, convenient chemical modication, rapid tissue penetration, and elimination of adverse toxicity.…”

Section: Aptamer-drug Conjugatesmentioning

confidence: 99%